The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Reciprocal influence of the p53 and the hypoxic pathways
Open accessAbstract
When cells sense a decrease in oxygen availability (hypoxia), they develop adaptive responses in order to sustain this condition and survive. If hypoxia lasts too long or is too severe, the cells eventually die. Hypoxia is also known to modulate the p53 pathway, in a manner dependent or not of HIF-1 (hypoxia-inducible factor-1), the main transcription factor activated by hypoxia. The p53 protein is a transcription factor, which is rapidly stabilised by cellular stresses and which has a major role in the cell responses to these stresses. The aim of this review is to compile what has been reported until now about the interconnection between these two important pathways. Indeed, according to the cell line, the severity and the duration of hypoxia, oxygen deficiency influences very differently p53 protein level and activity. Conversely, p53 is also described to affect HIF-1α stability, one of the two subunits of HIF-1, and HIF-1 activity. The direct and indirect interactions between HIF-1α and p53 are described as well as the involvement in this complex network of their respective ubiquitin ligases von Hippel Lindau protein and murine double minute 2. Finally, the synergistic or antagonistic effects of p53 and HIF-1 on some important cellular pathways are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 4×
“Although HIF-1b is constitutively expressed, HIF-1a is precisely regulated by hypoxia.(1) On the other hand, p53”
BackgroundInfluentialThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“As previously described, pVHL has a negative role on HIF-1a(98) and MDM2 on p53.(5,6) However HIF-1a has a positive role on pVHL(99) and p53 on MDM2(100) because these regulators are target genes of the Reciprocal influence of p53 and hypoxia A Sermeus and C Michiels”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“As previously described, pVHL has a negative role on HIF-1a(98) and MDM2 on p53.(5,6) However HIF-1a has a positive role on pVHL(99) and p53 on MDM2(100) because these regulators are target genes of the Reciprocal influence of p53 and hypoxia A Sermeus and C Michiels”
BackgroundLive or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Cited by
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054
Senescence and aging: the critical roles of p53
Rufini, A., Tucci, P., Celardo, I., & Melino, G. (2013) · Oncogene · doi:10.1038/onc.2012.640 · Cited by 798
Magnesium silicide nanoparticles as a deoxygenation agent for cancer starvation therapy
Zhang, C., Ni, D., Liu, Y., Yao, H., Bu, W., & Shi, J. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2016.280 · Cited by 413
Cancer metabolism: current perspectives and future directions
Muñoz-Pinedo, C., El Mjiyad, N., & Ricci, J.-E. (2012) · Cell Death & Disease · doi:10.1038/cddis.2011.123 · Cited by 385
Lacroix, M., Riscal, R., Arena, G., Linares, L. K., & Le Cam, L. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.10.002 · Cited by 373
Masson, N., & Ratcliffe, P. J. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-3 · Cited by 298
Hypoxia: A master regulator of microRNA biogenesis and activity
Nallamshetty, S., Chan, S. Y., & Loscalzo, J. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.022 · Cited by 281
Choi, Y.-M., Kim, H.-K., Shim, W., Anwar, M. A., Kwon, J.-W., Kwon, H.-K., Kim, H. J., Jeong, H., Kim, H. M., Hwang, D., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135083 · Cited by 279
Artificial Enzyme Catalyzed Cascade Reactions: Antitumor Immunotherapy Reinforced by NIR‐II Light
Wen, M., Ouyang, J., Wei, C., Li, H., Chen, W., & Liu, Y. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201909729 · Cited by 269
The complexity of p53-mediated metabolic regulation in tumor suppression
Liu, Y., & Gu, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 261
HIF-1 in cancer therapy: two decade long story of a transcription factor
Soni, S., & Padwad, Y. S. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1301680 · Cited by 251
Senescent Cardiac Fibroblast Is Critical for Cardiac Fibrosis after Myocardial Infarction
Zhu, F., Li, Y., Zhang, J., Piao, C., Liu, T., Li, H.-H., & Du, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074535 · Cited by 201
Hypoxia and Selective Autophagy in Cancer Development and Therapy
Daskalaki, I., Gkikas, I., & Tavernarakis, N. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00104 · Cited by 188
GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases
Fujita, Y., Ito, M., Kojima, T., Yatsuga, S., Koga, Y., & Tanaka, M. (2015) · Mitochondrion · doi:10.1016/j.mito.2014.10.006 · Cited by 128
Botting, K. J., McMillen, I. C., Forbes, H., Nyengaard, J. R., & Morrison, J. L. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000531 · Cited by 111
Targeting Therapies for the p53 Protein in Cancer Treatments
Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84
Metadata
- Authors
- Sermeus, A., & Michiels, C.
- Venue
- Cell Death & Disease
- Published
- 2011-05-26
- Volume
- 2
- Issue
- 5
- Pages
- e164-e164
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2087145462
- Cited by
- 265
- References
- 120
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.